Health economics of disease-modifying therapy for multiple sclerosis in the United States

Multiple sclerosis (MS) is chronic neuroinflammatory condition associated with significant disability. The economic burden of MS is substantial, and high and rising disease-modifying therapy (DMT) prices are the single largest drivers of healthcare expenditures. Over much of the last decade, price increases for most DMTs have surpassed 10% annually. Currently, many MS DMTs exceed US$90,000 a year and their economic value is widely debated. In addition to creating a financial burden for the healthcare system, high DMT costs negatively impact patients through unaffordable out-of-pocket costs and excessive restrictions by insurance companies. The objective of this narrative review is to summarize economic issues related to MS DMTs, including trends in pricing, relative value, and effects on patient care in the United States.

Automated summary

Multiple sclerosis (MS) is a chronic neuroinflammatory condition that is associated with significant disability. The high and rising prices of disease-modifying therapies (DMTs) for MS are a major driver of healthcare expenditures. The cost burden of DMTs negatively affects both healthcare systems and patients.